Table 5.

Univariate and multivariate analyses of clinical factors at the start of irinotecan plus fluorouracil/folinic acid (nal-IRI/FF) treatment for predicting overall survival.

Variables at the Start of nal-IRI/FF Treatment	n	Univariate			Multivariate
		HR	(95% CI)	p-Value	HR	(95% CI)	p-Value
Age
≥70 y.o.	20	1.17	(0.57–2.38)	0.67
<70 y.o.	20
Sex
male	19	1.06	(0.52–2.17)	0.86
female	21
ECOG PS
=1 or 2	19	3.08	(1.43–6.63)	0.004	2.24	0.86–5.73	0.09
=0	21
Stage
metastatic	31	1.40	(0.57–3.46)	0.51
locally advanced	9
Liver metastasis
present	19	1.12	(0.54–2.32)	0.67
absent	21
Peritoneal metastasis
present	14	1.12	(0.54–2.33)	0.76
absent	26
Carcinomatosis *
present	19	1.44	(0.71–2.93)	0.31
absent	21
NLR
>4	10	4.88	(2.10–11.3)	0.0002	3.08	1.21–7.85	0.02
≤4	30
CA19-9
>1000 U/dL	20	1.38	(0.67–2.80)	0.37
≤1000 U/dL	16
GPS
=2	11	2.08	(0.94–4.59)	0.07
=0.1	29
LMR
<3	27	1.18	(0.55–2.52)	0.67
≥3	13
PLR
>150	32	0.80	(0.35–1.83)	0.60
≤150	8
PNI
<45	30	0.78	(0.35–1.71)	0.53
≥45	10
Bodyweight decrease from the diagnosis as an unresectable disease
>5%	14	2.29	(1.09–4.85)	0.03	1.46	0.64–3.32	0.37
≤5%	23
The interval from the diagnosis to the administration of nal-IRI/FF
>6.6months	20	1.04	0.51–2.14	0.95
≤6.6months	20

* Carcinomatosis, presence of multi-metastatic sites; GPS, Glasgow prognostic score. NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; LMR, lymphocyte-monocyte ratio; PNI, prognostic nutritional index.